Combination therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a type of liver cancer called hepatocellular carcinoma that cannot be removed by surgery.
- Your cancer must have at least one untreated tumor larger than 5 cm that can be treated with ablation (a procedure that destroys tumors using heat or cold).
- You should be generally active (able to do light work or care for yourself) and expected to live more than 3 months.
- If you've had previous cancer treatments, your disease must have stayed the same or grown after those treatments.
- Your liver function must be reasonably good (Child-Pugh score 7 or lower).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment that uses heat (ablation) and other therapies to destroy liver tumors. It's for people who cannot have surgery or choose not to, and whose tumor is a specific size.
This trial tests a heat-based treatment for liver cancer tumors that uses multiple methods to destroy cancer cells. It may help people with liver tumors that haven't spread and who are healthy enough for treatment.
This trial tests whether combining heat-based treatment of a tumor with immunotherapy drugs can help people with advanced liver cancer that cannot be surgically removed. The goal is to shrink tumors and improve survival by using the body's immune system alongside localized heat treatment.
This study tests a combination therapy for liver cancer that cannot be surgically removed. It includes a procedure called TACE (which blocks the tumor's blood supply), along with targeted therapy (lenvatinib), immunotherapy (tislelizumab), and a blood pressure medicine (carvedilol) that may also help the liver. The goal is to see if this combination is safe and effective for people who also have high blood pressure in the liver's blood vessels.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
Hear when a new Neoplasms, Glandular and Epithelial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.